homovanillic acid

Homovanillic acid (Vanillacetic acid), a dopamine metabolite, is linked to aromatic L-amino acid decarboxylase deficiency, growth hormone deficiency, celiac disease, and sepiapterin reductase deficiency.

Homovanillic acid sulfate (sodium) is a phenolic compound found in olive oil and a metabolite of dopamine. It increases in the body during acute kidney injury and serves as a biomarker for the early detection of kidney diseases.

Homovanillic acid-d3 is a deuterated compound of Homovanillic acid.

Homovanillic acid sulfate is used as a reagent to detect oxidative enzymes, and is associated with dopamine levels in the brain.In psychiatry and neuroscience, brain and cerebrospinal fluid levels of homovanillic acid are measured as a marker of metabolic

Homovanillic acid-d5 (Vanilacetic acid-d5) is a deuterated Homovanillic acid, which can be used to study the metabolism of Homovanillic acid in vivo. Homovanillic acid is a dopamine metabolite, which is an indicator of central dopamine function in primates. Homovanillic acid is a dopamine metabolite and an indicator of central dopamine function in primates.

Homovanillic Acid-13C-d3 the 13C and deuterated compound of Homovanillic Acid. Homovanillic Acid has a CAS number of 306-08-1. Homovanillic acid is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, celiac disease, growth hormone deficiency, and sepiapterin reductase deficiency.

Homovanillic acid (Standard) is a reference standard for research and analysis in studies involving Homovanillic acid. Homovanillic acid (Vanillacetic acid) is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, growth hormone deficiency, celiac disease, and sepiapterin reductase deficiency.

Isohomovanillic acid (Homoisovanillic acid is used as pharmaceutical intermediates.

CGP-28014 is an inhibitor of catechol-O-methyltransferase. CGP-28014 increases the renal excretion of both dopamine and dihydroxyphenylacetic acid (DOPAC) but does not affect renal sodium handling indicating a different mechanism of action. CGP-28014 sign

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).

N,N-Dipropyldopamine is a dopamine receptor agonist.1,2,3 It decreases dihydrophenylalanine (DOPA) levels in the limbic forebrain and striatum of reserpinized rats (ED50s = 25 and 20 μmol/kg, respectively), as well as reduces homovanillic acid levels in rat striatum when administered at a dose of 80 μmol/kg.1 N,N-Dipropyldopamine (0.5-16 mg/kg) reduces spontaneous locomotor activity in mice, an effect that can be reversed by the antipsychotic spiroperidol.2,3

(4-Hydroxy-3-methoxyphenyl)acetic-2,2-d2 Acid is a deuterated compound of (4-Hydroxy-3-methoxyphenyl)acetic Acid. (4-Hydroxy-3-methoxyphenyl)acetic Acid has a CAS number of 306-08-1. Homovanillic acid is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, celiac disease, growth hormone deficiency, and sepiapterin reductase deficiency.